“…From the availability of new direct‐acting anti‐retrovirals (DAAs) for treatment of hepatitis C (Chung et al, ), SVR can reach levels of almost 100% (Liang & Ghany, ), and thus, EHMs can be controlled when the immune tolerance is indirectly restored (Comarmond et al, ). The same has been reported for the treatment of OLP‐HCV, that is, exacerbation of OLP lesions occurs when hepatitis C is treated with interferon and ribavirin (Grossmann, Teixeira, de Aguiar, & do Carmo, ; Nagao, Kawaguchi, Ide, Kumashiro, & Sata, ), and their cure occurs in patients undergoing interferon‐free therapy with DAAs (Misaka, Kishimoto, Kawahigashi, Sata, & Nagao, ; Nagao, Kimura, Kawahigashi, & Sata, ).…”